Enzalutamide for patients with metastatic castration-resistant prostate cancer

OBJECTIVE: To review and evaluate current literature on the US Food and Drug Administration (FDA)-approved drug enzalutamide (XTANDI(®)) in metastatic castration-resistant prostate cancer. DATA SOURCES: Literature search was done through PubMed using the terms enzalutamide, MDV3100, abiraterone, and...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Onco Targets Ther
Asıl Yazarlar: Ramadan, Wijdan H, Kabbara, Wissam K, Al Basiouni Al Masri, Hiba S
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Dove Medical Press 2015
Konular:
Review
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4407758/
https://ncbi.nlm.nih.gov/pubmed/25945058
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S80488
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller